REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP)...

menu
menu